Nahdi Medical Company Just Recorded A 10% Revenue Beat: Here's What Analysts Think

Investors in Nahdi Medical Company (TADAWUL:4164) had a good week, as its shares rose 6.1% to close at ر.س121 following the release of its first-quarter results. Nahdi Medical beat revenue forecasts by a solid 10% to hit ر.س2.6b. Statutory earnings per share came in at ر.س6.31, in line with expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the current consensus from Nahdi Medical's five analysts is for revenues of ر.س10.5b in 2025. This would reflect an okay 6.6% increase on its revenue over the past 12 months. Statutory per-share earnings are expected to be ر.س6.51, roughly flat on the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of ر.س10.1b and earnings per share (EPS) of ر.س6.41 in 2025. There doesn't appear to have been a major change in sentiment following the results, other than the small increase to revenue estimates.

Check out our latest analysis for Nahdi Medical

It may not be a surprise to see thatthe analysts have reconfirmed their price target of ر.س130, implying that the uplift in revenue is not expected to greatly contribute to Nahdi Medical's valuation in the near term. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Nahdi Medical, with the most bullish analyst valuing it at ر.س160 and the most bearish at ر.س110 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Nahdi Medical's growth to accelerate, with the forecast 8.9% annualised growth to the end of 2025 ranking favourably alongside historical growth of 5.2% per annum over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 6.3% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Nahdi Medical to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target held steady at ر.س130, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Nahdi Medical going out to 2027, and you can see them free on our platform here..

You still need to take note of risks, for example - Nahdi Medical has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.